RGC — Regencell Bioscience Holdings Income Statement
0.000.00%
- $44.50m
- $44.50m
Annual income statement for Regencell Bioscience Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.391 | 0.812 | 1.38 | 7.62 | 6.27 |
Operating Profit | -0.391 | -0.812 | -1.38 | -7.62 | -6.27 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.391 | -0.812 | -1.35 | -7.59 | -6.06 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.391 | -0.812 | -1.35 | -7.59 | -6.06 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.391 | -0.812 | -1.35 | -7.45 | -5.87 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.391 | -0.812 | -1.35 | -7.45 | -5.87 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.031 | -0.064 | -0.107 | -0.581 | -0.451 |
Dividends per Share |